Signaling and transcriptional control of Fas ligand expression

Cell Death and Differentiation

Volumn 10, Issue 1, 2003, Pages 36-44

  Kavurma, M M ^a,b   Khachigian, L M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Apoptosis; Fas ligand; Gene expression; Transcription factor

Indexed keywords

CASEIN KINASE I; CASPASE; CYTOCHROME C; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MYC PROTEIN; SYNAPSIN I; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR;

APOPTOSIS; ATHEROSCLEROSIS; CELL DEATH; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CYTOKINES; FAS LIGAND PROTEIN; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION REGULATION; GENES, REGULATOR; HUMANS; MEMBRANE GLYCOPROTEINS; SIGNAL TRANSDUCTION; STRESS;

EID: 0037274017     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401179     Document Type: Review

References (99)

1. Nagata S (1999) Fas ligand-induced apoptosis. Annu. Rev. Genet. 33: 29-55
2. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F (1999) The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20: 46-52
3. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH and Nagata S (1996) Fas ligand in human serum. Nat. Med. 2: 317-322
4. Tanaka M, Suda T, Takahashi T and Nagata S (1995) Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14: 1129-1135
5. Orlinick JR, Elkon KB and Chao MV (1997) Separate domains of the human Fas Ligand dictate self-association and receptor binding. J. Biol. Chem. 272: 32221-32229
6. Blott EJ, Bossi G, Clark R, Zvelebil M and Griffiths GM (2001) Fas Ligand is targeted to secretory lysosomes via a proline-rich domain in the cytoplasmic tail. J. Cell. Sci. 114: 2405-2416
7. Wenzel J, Sanzenbacher R, Ghadimi M, Lewitzky M, Zhau Q, Kaplan DR, Kabelitz D, Feller SM and Janssen O (2001) Multiple interactions of the cytosolic polypropoline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor. FEBS Lett. 509: 255-262
8. Budihardjo I, Oliver H, Lutter M, Luo X and Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15: 269-290
9. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem. J. 326: 1-16
10. L. Proc. Natl. Acad. Sci. USA 96: 14871-14876
11. Dhein J, Walczak H, Baumler C, Debatin KM and Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441
12. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF and Green DR (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441-444
13. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ and Marshak-Rothstein A (1995) Fas(CD95) FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448
14. Russell JH, Rush B, Weaver C and Wang R (1993) Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA 90: 4409-4413
15. Giese T and Davidson WF (1994) Chronic treatment of C3H-Ipr/lpr and C3H-gld/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production. J. Immunol. 152: 2000-2010
16. Watanabe D, Suda T and Nagata S (1995) Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int. Immunol. 7: 1949-1956
17. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis MM and Goodnow CC (1995) CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376: 181-184
18. Fukuyama H, Adachi M, Suematsu S, Miwa K, Suda T, Yoshida N and Nagata S (2002) Requirement of Fas expression in B cells for tolerance induction. Eur. J. Immunol. 32: 223-230
19. Smyth MJ, Kelly JM, Sutton VR, Davis JE, Browne KA, Sayers TJ and Trapani JA (2001) Unlocking the secrets of cytotoxic granule proteins. J. Leuk. Biol. 70: 18-29
20. Shi L, Mai S, Israels S, Browne K, Trapani JA and Greenberg AH (1997) Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J. Exp. Med. 185: 855-866
21. Shi L, Chen G, He D, Bosc DG, Litchfield DW and Greenberg AH (1996) Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J. Immunol. 157: 2381-2385
22. Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR and Bleackley RC (2000) Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic. T-lymphocyte killing by directly cleaving Bid. Mol. Cell. Biol. 20: 3781-3794
23. Kagi D, Ledermann B, Burki K, Hengartner H and Zinkernagel RM (1994) CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur. J. Immunol. 24: 3068-3072
24. Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178
25. Rouvier E, Luciani MF and Golstein P (1993) Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J. Exp. Med. 177: 195-200
26. Ramsdell F, Seaman MS, Miller RE, Tough TW, Alderson MR and Lynch DH (1994) gld/gld mice are unable to express a functional ligand for Fas. Eur. J. Immunol. 24: 928-933
27. Janin A, Deschaumes C, Daneshpouy M, Estaquier J, Micic-Polianski J, Rajagopalan-Levasseur P, Akarid K, Mounier N, Gluckman E, Socie G and Ameisen JC (2002) CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood 99: 2940-2947
28. Nagata S (1997) Apoptosis by death factor. Cell 88: 355-365
29. Griffith TS, Brunner T, Fletcher SM, Green DR and Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege, Science 270: 1189-1192
30. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X and Ferguson TA (1997) CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99: 396-402
31. Lau HT, Yu M, Fontana A and Stoeckert CJJ (1996) Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273: 109-112
32. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A and Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630-632
33. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F (1999) Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas Ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 12: 83-89
34. Chappell DB and Restifo NP (1998) T cell-tumor cell: a fatal interaction? Cancer Immunol. Immunother. 47: 65-71
35. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J and Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366
36. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK and Shanahan F (1998) The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160: 5669-5675
37. Restifo NP (2001) Countering the 'counterattack' hypothesis. Nat. Med. 7: 259
38. Allison J, Georgiou HM, Strasser A and Vaux DL (1997) Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94: 3943-3947
39. Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat. Med. 6: 493-495
40. Isner JM, Kearney M, Bortman S and Passeri J (1995) Apoptosis in human atherosclerosis and restenosis. Circulation 91: 2703-2711
41. Kockx M and De Meyer G (1996) Apoptosis in human atherosclerosis and restenosis. Circulation 93: 394-395
42. Pollman MJ, Hall JL, Mann MJ, Zhang L and Gibbons GH (1998) Inhibition of neointimal cell bc1-x expression induces apoptosis and regression of vascular disease. Nat. Med. 4: 222-227
43. Geng YJ, Henderson LE, Levesque EB, Muszynski M and Libby P (1997) Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17: 2200-2208
44. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P and Walsh K (1998) Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. USA 95: 1213-1217
45. Sata M and Walsh K (2000) Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels. J. Mol. Cell. Cardiol. 32: 1395-1400
46. Libby P, Geng YJ, Sukhova GK, Simon DI and Lee RT (1997) Molecular determinants of atherosclerotic plaque vulnerability. Ann. NY Acad. Sci. 811: 1
47. Mayr M and Xu Q (2001) Smooth muscle cell apoptosis in arteriosclerosis. Exp. Gerontol. 36: 969-987
48. Geng YJ, Liao H-S and Macgovern J (1998) Expression of FasL in advanced human atherosclerotic lesions: implications for co-occurrence of immunocytoxicity and immune privilege. Circulation 98 (Suppl I): I-48
49. Boyle JJ, Bowyer DE, Weissberg PL and Bennett MR (2001) Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Atheroscle. Thromb. Vasc. Biol. 21: 1402-1407
50. Shimizu M, Fukuo K, Nagata S, Suhara T, Okuro M, Fujii K, Higashino Y, Mogi M, Hatanaka Y and Ogihara T (2002) Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J. Am. Coll. Cardiol. 39: 585-590
51. Pinkoski MJ and Green DR (1999) Fas ligand, death gene. Cell Death Differ. 6: 1174-1181
52. Crabtree GR and Clipstone NA (1994) Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu. Rev. Biochem. 63: 1045-1083
53. Latinis KM, Norian LA, Eliason SL and Koretzky GA (1997) Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J. Biol. Chem. 272: 31427-31434
54. Rivera I, Harhaj EW and Sun S-C (1998) Involvement of NF-AT in type I human T-cell leukemia virus Tax-mediated Fas ligand promoter transactivation. J. Biol. Chem. 273: 22382-22388
55. Li XX and Stark GR (2002) NF kappa B-dependent signaling pathways. Exp. Hematol. 30: 285-296
56. Lee JI and Burckart GJ (1998) Nuclear factor kappa B: important transcription factor and therapeutic target. J. Clin. Pharmacol. 38: 981-993
57. Matsui K, Fine A, Zhu B, Marshak-Rothstein A and Ju ST (1998) Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J. Immunol. 161: 3469-3473
58. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR (1998) DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell 1: 543-551
59. Kasibhatla S, Genestier L and Green DR (1999) Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J. Biol. Chem. 274: 987-992
60. Kavurma MM, Santiago FS, Bonfoco E and Khachigian LM (2001) Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J. Biol. Chem. 276: 4964-4971
61. Kavurma MM, Bobryshev U and Khachigian LM (2002) Ets-1 positively regulates Fas ligand transcription via co-operative interactions with Sp1. J. Biol. Chem. (in press)
62. Xiao, S, Matsui K, Fine A, Zhu B, Marshak-Rothstein A, Widom RL and Ju ST (1999) FasL promoter activation by IL-2 through SP1 and NFAT but not Egr-2 and Egr-3. Eur. J. Immunol. 29: 3456-3465
63. Mittelstadt PR and Ashwell JD (1998) Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol. Cell. Biol. 18: 3744-3751
64. Silverman ES and Collins T (1999) Pathways of Egr-1-mediated gene transcription in vascular biology. Am. J. Pathol. 153: 665-670
65. Li-Webber M, Laur O and Krammer PH (1999) Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T cell stimulation. Eur. J. Immunol. 29: 3017-3027
66. Mittelstadt PR and Ashwell JD (1999) Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative 1pr and gId T cells. J. Biol. Chem. 274: 3222-3227
67. Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, Kroczek RA, Ashwell JD and Glimcher LH (2000) Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity 12: 293-300
68. Yang Y, Dong B, Mittelstadt PR, Xiao H and Ashwell JD (2002) HIV Tat binds Egr proteins and enhances Egr-dependent transactivation of the Fas Ligand promoter. J. Biol. Chem. 277: 19482-19487
69. Chow WA, Fang JJ and Yee JK (2000) The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J. Immunol. 164: 3512-3518
70. Kirschhoff S, Sebens T, Baumann S, Krueger A, Zawatzky R, Li-Webber M, Meinl E, Neipel F, Fleckenstein B and Krammer PH (2002) Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter. J. Immunol. 168: 1226-1234
71. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128
72. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP and Green DR (1992) Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257: 212-214
73. Bissonnette RP, McGahon A, Mahboubi A and Green DR (1994) Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. J. Exp. Med. 180: 2413-2418
74. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S and Evan GI (1997) Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278: 1305-1309
75. Brunner T, Kasibhatla S, Pinkoski MJ, Frutschi C, Yoo NJ, Echeverri F, Mahboubi A and Green DR (2000) Expression of Fas ligand in activated T cells is regulated by c-Myc. J. Biol. Chem. 275: 9767-9772
76. Kasibhatla S, Beere HM, Brunner T, Echeverri F and Green DR (2000) A 'non-canonical' DNA-binding element mediates the response of the Fas-Ligand promoter to c-Myc. Curr, Biol. 10: 1205-1208
77. Genestier L, Kasibhatla S, Brunner T and Green DR (1999) Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189: 231-239
78. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868
79. Suhara T, Kim H-S, Kirshenbaum LA and Walsh K (2002) Suppression of Akt signaling induces Fas Ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated FasL regulation. Mol. Cell. Biol. 22: 680-691
80. Faris M, Latinis KM, Kempiak SJ, Koretzky GA and Nel A (1998) Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol. Cell. Biol. 18: 5414-5424
81. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret F-X, Green DR and Karin M (1999) Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19: 751-763
82. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, Bofill M, Krajewski S, Reed JC and Salmon D (1996) Interleukin-2 receptor common gamma-chain signaling cytolkines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26: 294-299
83. Radvanyi LG, Raju K, Spaner D, Mills GB and Miller RG (1998) Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune 1pr mice. Cell. Immunol. 183: 1-12
84. Horak I, Lohler J, Ma A and Smith KA (1995) Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol. Rev. 148: 35-44
85. Haux J, Johnsen AC, Steinkjer B, Egeberg K, Sundan A and Espevik T (1999) The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis. Cancer Immunol. Immunother. 48: 139-146
86. Refaeli Y, Vanparijs L, London CA, Tschopp J and Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 615-623
87. Ayroldi E, Zollo O, Cannarile L, D'Adamio F, Grohmann U, Delfino DV and Riccardi C (1998) Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/FasL expression and cell death. Blood 92: 4212-4219
88. Teague TK, Marrack P, Kappler JW and Vella AT (1997) IL-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158: 5791-5796
89. Massague J (1990) The transforming growth factor-beta family. Annu. Rev. Cell Dev. Biol. 6: 597-641
90. Cerwenka A, Kovar H, Majdic O and Holter W (1996) Fas- and activation-induced apoptosis are reduced in human T cells preactivated in the presence of TGF-beta 1. J. Immunol. 156: 459-464
91. Schlapbach R, Spanaus K-S, Malipiero U, Lens S, Tasinato A, Tschopp J and Fontana A (2000) TGF-β induces the expression of the FLICE-inhibitory protein and inhibits Fas-mediated apoptosis of microglia. Eur. J. Immunol. 30: 3680-3688
92. Dünker N, Schmitta K and Krieglsteina K (2002) TGF-β is required for programmed cell death in interdigital webs of the developing mouse limb. Mech. Dev. 113: 111-120
93. Arsura M, Wu M and Sonenshein GE (1996) TGFβ1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of IκB. Immunity 5: 31-40
94. Yang Y, Mercep M, Ware CF and Ashwell JD (1995) Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorlicoids. J. Exp. Med. 181: 1673-1682
95. Lee MO, Kang HJ, Kim YM, Oum JH and Park J (2002) Repression of FasL expression by retinoic acid involves a novel mechanism of inhibition of transactivation function of the nuclear factors of activated T-cells. Eur. J. Biochem. 269: 1162-1170
96. Yang Y, Minucci S, Ozato K, Heyman RA and Ashwell JD (1995) Efficient inhibition of activation-induced Fas ligand up-regulation and T cell apoptosis by retinoids requires occupancy of both retinoid X receptors and retinoic acid receptors. J. Biol. Chem. 270: 18672-18677
97. Melino G, Bernassola F, Catani MV, Rossi A, Corazzari M, Sabatini S, Vilbois F and Green DR (2000) Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation. Cancer Res. 60: 2377-2383
98. Cippitelli M, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M and Fra Santoni A (2002) Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J. Immunol. 168: 1154-1166
99. Bodor J, Bodorova J, Bare C, Hodge DL, Young HA and Gress RE (2002) Differential inducibility of the transcriptional repressor ICER and its role in modulation of Fas ligand expression in T and NK lymphocytes. Eur. J. Immunol. 32: 203-212